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Abstract
Purpose of Review To evaluate recent developments in the management of hypertension in obese pregnant women.
Recent Findings The mainstay of management targets prevention of hypertension with preconception counselling, entering
pregnancy with a lower BMI, limiting weight gain, and taking low-dose aspirin to prevent pre-eclampsia from before 16 weeks’
gestation. There are conflicting results regarding the use of metformin in reducing hypertensive disease, but there is a high
probability that it has a role to play. Clinical trials are in progress examining the use of statins in preventing pre-eclampsia, with
promising results from pre-clinical trials. Home blood pressure monitoring may be helpful in diagnosing and monitoring the
control of hypertension.
Summary The most protective interventions against hypertensive disease in obese pregnant women are entering pregnancy at a
lower BMI, avoiding inter-pregnancy weight gain, and taking low-dose aspirin during pregnancy. Further research is needed
around the use of metformin, statins, and home blood pressure monitoring.
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Introduction
Obesity is associated with an increasingly huge impact on
healthcare globally. Its effect in pregnancy has both imme-
diate and long-term implications on the maternal and child
health. The prevalence of obesity in the UK population is
increasing, and it is estimated that approximately 1 in 20
pregnant women have a body mass index (BMI) of over
35 kg/m2 [1]. This not only represents a huge challenge to
maternity services, but also represents a sizeable financial
burden at a time when healthcare funding is continually
being cut [2]. There has been a concerted effort to try to
reduce obesity levels in the general population given the
mounting evidence that it is associated with multiple co-
morbidities, including diabetes, cardiovascular disease, hy-
pertension, gastro-intestinal disease, and psychiatric mor-
bidities [3]. There is now also a growing body of evidence
that, during pregnancy, there is a significant effect on the
offspring’s health, increasing their likelihood of stillbirth,
requiring admission to the neonatal unit, being large for
gestational age, and being obese themselves as children
[1, 2]. Efforts have focused on preconception counselling,
limiting weight gain during pregnancy, exploring pharma-
cological options, and improving blood pressure monitor-
ing in order to prevent and better manage hypertensive
disorders associated with obese pregnant women.
Obesity in Pregnancy
In the most recent Health Survey for England, the prevalence
of adult obesity was 27% in women, with 4% of women being
morbidly obese. This means that their body mass index, cal-
culated by taking into account their height and their weight, is
above 30 kg/m2 or above 40 kg/m2, respectively [4]. This
translates into an increasing number of obese women falling
pregnant and is associated with a higher prevalence of co-
morbid conditions and both maternal and fetal complications
(Fig. 1) [1].
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Morbidity and mortality are incrementally higher with each
increase in BMI category, subdivided into Class I (> 30 kg/m2),
Class II (> 35 kg/m2), Class III or morbid obesity (> 40 kg/m2),
and super-morbid obesity (> 50 kg/m2). The prevalence of
women with a BMI above 35 kg/m2 who gave birth beyond
24 weeks gestation is 5%, with 2% being in the Class III
category and 0.2% being the super-morbid obesity catego-
ry [1, 3, 4]. Women in the higher BMI categories had a
significant increase in the incidence of pregnancy-induced
hypertension, pre-eclampsia, and severe pre-eclampsia [1].
Systematic reviews have concluded that there is a direct rela-
tionship between obesity and pre-eclampsia with a 3 to 10
times increase in the risk in obese women [5]. This, in turn,
impacts negatively on the likelihood of spontaneous vaginal
delivery without instrumentation and increases the rate of cae-
sarean section, postpartum haemorrhage, longer hospital
stays, neonatal admissions, stillbirths, and infant death [1].
Longer term, there is a life-long risk of cardiovascular disease
in both the mother and the offspring. This includes hyperten-
sion, ischaemic heart disease, and stroke with some studies
finding a two to eightfold increase in the risk of developing
cardiovascular disease following a pregnancy complicated by
pre-eclampsia [5, 6]. It is clear that a holistic and multi-faceted
approach is key in ensuring the optimal management of the
obese hypertensive pregnant woman, in order to reduce the
immediate and long-term health implications for both the
mother and offspring.
Preconception Counselling
Cardiovascular disease is associated with a number of modi-
fiable risk factors including smoking, hypertension, hyperlip-
idaemia, sedentary lifestyle, and insulin resistance [6, 7].
Women of childbearing age contemplating pregnancy repre-
sent a window of opportunity to target these risk factors. By
optimising their health prior to pregnancy, they benefit from
improved fertility, more uncomplicated pregnancies and de-
liveries, healthier offspring, and better long-term health, both
physical and mental [5]. Many women are unaware of the
implications obesity has on their health and their fertility.
Educating them about the lifestyle changes that can optimise
their chances of a successful pregnancy can aid them in mak-
ing informed decisions about timing their conception. The aim
of improving their fertility can act as a positive driving force to
introduce and maintain those lifestyle changes [5, 8, 9].
The main objective is to encourage women to achieve a
BMI within the normal range of 18.5–24.9 kg/m2 [3, 10].
However, a reduction in pre-pregnancy BMI of even 10%
has been shown to reduce the risk of pre-eclampsia by 10%
[11]. The timing of this counselling needs to be explored as
this is information that potentially needs to be disseminated
from a young age in order to tackle rising obesity rates well
before the point of falling pregnant [10]. There is an associa-
tion between weight reduction around the time of conception
and adverse perinatal outcomes such as low birth weight, pre-
term delivery, and longer-term health implications in offspring
like cardiovascular disease, impaired glucose tolerance, ob-
structive airways disease, schizophrenia, and breast cancer
as adults [10, 12]. Therefore, women undergoing bariatric
surgery are encouraged to wait 1–2 years before falling preg-
nant in order to avoid the period of most rapid weight loss and
malabsorption [10].
Unfortunately, the availability of preconception services
and women’s engagement with these services is lacking.
According to the organisational survey of UKmaternity units,
only 6% of obstetric units offer preconception services to
women with a BMI over 30 kg/m2 [1]. Even where the ser-
vices exist, less than half of the women, it is designed to reach,
engage with them [9]. This does not take into account the
Fig. 1 The prevalence and impact of obesity in pregnancy
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advice given in the primary care setting, but this does high-
light the need for more opportunities to provide individualised
preconception counselling to obese women planning to get
pregnant.
Weight Gain
Many studies have focused on the effects of weight gain dur-
ing pregnancy and during the inter-pregnancy interval. Weight
gain during pregnancy has been associated with an increased
risk of developing gestational diabetes, large for gestational-
age babies, insulin resistance in the offspring, and stillbirths,
but also can increase the BMI in the postpartum period leading
to increased BMI in subsequent pregnancies [10, 13, 14].
When looking at hypertensive disorders, excessive weight
gain during pregnancy has been associated with increased
risks of developing gestational hypertension and pre-
eclampsia [15, 16]. The difficulty arises that although women
are advised to avoid excessive gestational weight gain, no
intervention has currently been found that significantly re-
duces maternal and fetal adverse outcomes. The UPBEAT
study looked at the clinical outcomes of obese pregnant wom-
en after supporting them with health trainer–led sessions to
improve diet and physical activity. Unfortunately, these be-
havioural interventions did not significantly reduce the risk
of pre-eclampsia or any other adverse outcomes [17]. A sim-
ilar study in Australia found that support through a dietician
and setting goals for dietary change and exercise did not sig-
nificantly impact the incidence of hypertensive disease in
pregnancy either [18].
There is now more focus on trying to avoid weight gain in
between pregnancies. It seems that entering pregnancy with a
healthier BMI is associated with better immediate and long-
term outcomes [5, 10, 14, 16]. The inter-pregnancy weight
gain is directly linked to an increased risk of developing hy-
pertensive disease in subsequent pregnancies. For gestational
hypertension and for pre-eclampsia, the risk increases with
increasing BMI with a relative risk of 2.24 and 1.64 for a
BMI increase of 3 kg/m2 respectively (Table 1) [14]. It is also
related to an increased risk of hypertensive disease later in life
[6, 10]. It is therefore essential to target women in the postnatal
period in order to educate them and support them to achieve
their weight loss goals and not carry the weight through to the
next pregnancy or later in life [16].
Aspirin
The use of aspirin in pregnancy has been put forward in order
to try to prevent a number of adverse pregnancy outcomes,
including preterm deliveries, intrauterine fetal growth restric-
tion, miscarriages, and stillbirths. The most common use of
aspirin in pregnancy is to reduce the risk of pre-eclampsia or to
delay its onset [16, 19]. Given the association of obesity with
all of the aforementioned adverse outcomes, aspirin has been
recommended for use in women with a BMI over 35 kg/m2
who have at least one other moderate risk factor for pre-
eclampsia [20].
The optimal dose of aspirin is yet to be ascertained, with an
initial recommendation of having 75 mg once a day [21]. It
was found that there was a 10% reduction in the risk of pre-
eclampsia when taking a dose of at least 75 mg once a day and
that this benefit was lost when aspirin was started after
20 weeks gestation [22, 23]. Further to this, it was noted that
the maximal beneficial effect was obtained if aspirin was
started before 16 weeks’ gestation [24]. A dose-dependent
benefit was also observed and, as a result, the ASPRE study
was set up across 13 countries in order to determine the effect
of 150 mg of aspirin daily started at between 11 and 14 weeks’
gestation and continued until 36 weeks’ gestation. There was a
significant reduction in the occurrence of preterm pre-
eclampsia in women with singleton pregnancies who were
found to be at high risk of pre-eclampsia with an odds ratio
of 0.38 (see Table 2). Specifically, there was a reduction of
new-onset hypertension with proteinuria. There were, howev-
er, no significant differences in the development of preterm or
term gestational hypertension without proteinuria [25].
The safety of the use of aspirin has been well documented
with no negative maternal or perinatal outcomes and only
10% of women experiencing gastro-intestinal discomfort
[22]. It is therefore now a widely used and widely recom-
mended treatment for the prevention of pre-eclampsia.
Metformin
There is conflicting data supporting the use of metformin as a
treatment for hypertensive disorders in pregnancy. It is widely
used to treat gestational diabetes and is considered safe for use
in pregnancy [26]. Metformin is a drug that increases tissue
sensitivity to insulin, thus lowering glucose levels in the
blood. It inhibits gluconeogenesis in the liver and improves
uptake of glucose into the skeletal muscles and fat cells, but
has also been linked with improved cardiovascular function
and is nephro-protective [27].
The EMPOWaR study randomised non-diabetic women
with a BMI over 30 kg/m2 to receive metformin initiated at
12–16 weeks’ gestation in order to determine its effect on fetal
birth weight. As a secondary outcome, it looked at the inci-
dence of adverse maternal outcomes, including pregnancy-
induced hypertension and pre-eclampsia. There was no statis-
tically significant reduction in the women receiving metfor-
min [28]. Conversely, a similar study randomising women
with a BMI over 35 kg/m2 to receive 3 g of metformin a day
from 12 to 18 weeks’ gestation until delivery, not only found a
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statistically significant lower incidence of pre-eclampsia but
also reduced weight gain during pregnancy [26].
A Cochrane review on the use of metformin in obese preg-
nant women conducted in 2017 included these two studies and
only one other study from Egypt, emphasising the paucity of
studies addressing this topic. They were able to include data
on 1099 participants and stated that metforminmaymake little
or no difference in the context of prevention of gestational
hypertension or pre-eclampsia in obese pregnant women
[29]. Since then, a systematic review and meta-analysis has
been published including 15 studies. Again, with regard to
obese pregnant women, no statistically significant difference
was demonstrated in treating hypertensive diseases in preg-
nancy with the use of metformin. The meta-analysis was able
to extrapolate that there was a high probability of over 90%
that metformin has a beneficial effect in preventing pre-
eclampsia, gestational hypertension, and any hypertensive dis-
ease in pregnancy, when compared to placebo or other treat-
ments. However, the low quality of evidence and the hetero-
geneity of the studied outcomes and results made it difficult to
make recommendations for wider use [30]. More research is
required in order to fully understand the impact that metformin
can have on its own or in combination with other treatments.
Statins
Statins have long been used in the primary and secondary
prevention of atherosclerotic cardiovascular disease [31].
Their use in women of childbearing age is increasing with
the rise in obesity and accompanying rise in cholesterol levels.
Although limited data is available with regard to their use and
safety in pregnancy, inadvertent exposure is occurring when
unplanned pregnancies occur [32].
Earlier studies found that there was an increased risk of
teratogenic effects following exposure to statins. This has
not been supported by more recent studies, and in fact, statins
have been shown to be safe and have therapeutic effects in the
context of pre-eclampsia in pre-clinical trials [32, 33].
Pravastatin in particular has been shown to have anti-inflam-
matory, anti-thrombogenic, and antioxidant effects resulting
in lower pre-eclampsia-related markers and improved endo-
thelial function [33]. The StAmP study is a multicentre UK
trial that recruited 62 women with singleton pregnancies di-
agnosed with pre-eclampsia between 24 and 32 weeks gesta-
tion in order to determine the clinical benefits of pravastatin in
pre-eclampsia. A publication with their outcome data is still
awaited [34]. A similar study in the USA, titled “Pravastatin
Table 1 Relative risks (95%
confidence intervals) of maternal
hypertensive disease in the
second pregnancy based on
increase in pre-pregnancy body
mass index (BMI) in women who
are nulliparous at baseline without
hypertensive disease in the first
pregnancy (n = 42,399) [14]
Outcome in the second pregnancy BMI change (in kg/m2)
< 1 1 to < 2 2 to < 3 > 3
Pre-eclampsia (n = 464)
Unadjusted 1.13 1.11 1.04 2.24
(0.84–1.50) (0.84–1.48) (0.72–1.49) (1.78–2.82)
Adjusted 0.84 0.98 0.87 1.64
(0.63–1.13) (0.74–1.31) (0.60–1.26) (1.27–2.11)
Gestational hypertension (n = 587)
Unadjusted 1.07 1.35 1.20 2.90
(0.81–1.40) (1.05–1.72) (0.87–1.65) (2.38–3.53)
Adjusted 0.78 1.24 1.03 2.24
(0.59–1.03) (0.97–1.59) (0.75–1.42) (1.82–2.76)
Adjusted for maternal race, inter-pregnancy interval, maternal age, marital status, smoking, and alcohol use during
the second pregnancy, pre-pregnancy BMI, gestational diabetes mellitus, pre-eclampsia, and gestational hyper-
tension in the first pregnancy
Table 2 Outcomes for hypertensive disease in trial group [25]
Outcome Aspirin group (n = 798) Placebo group (n = 822) Odds ratio (95% or 99% CI)*
Primary outcome: pre-eclampsia at < 37 weeks gestation 13 (1.6) 35 (4.3) 0.38 (0.20–0.74)
Secondary outcomes: pre-eclampsia at < 34 weeks gestation 3 (0.4) 15 (1.8) 0.18 (0.03–1.03)
Gestational hypertension at < 37 weeks gestation 8 (1.0) 7 (0.9) 1.19 (0.31–4.56)
Gestational hypertension at < 34 weeks gestation 2 (0.3) 2 (0.2) 1.02 (0.08–13.49)
*Confidence interval for primary outcomes 95% and secondary outcomes 99%
The values represent the actual numbers and those in the brackets represent percentage (%)
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for Prevention of Preeclamsia” is in its final stages [35]. The
outcomes from both of those studies will hopefully help to
guide the future use of statins in pregnancy.
Home Blood Pressure Monitoring
Historically, monitoring for hypertensive disease in pregnancy
has relied upon women’s regular attendance at antenatal visits,
with blood pressure checks at each visit. In women identified
as being at high risk of developing pre-eclampsia, more fre-
quent blood pressure measurements are recommended, but no
timings or intervals are specified [36]. In primary care settings,
the use of home blood pressure monitoring devices in the
management of hypertension has been incorporated as part
of a strategy to involve the patient in the management of their
own care. It has been used to good effect resulting in signifi-
cantly lower blood pressure readings compared to titration of
antihypertensive medication based on clinic readings alone
[37].
Extended to the pregnant population at risk of or having
already developed hypertensive disease, a home blood pres-
sure monitoring strategy can help to manage women more
accurately without increasing their risk of adverse outcomes.
As a secondary effect, it may also reduce the number of visits
to hospital in the context of outpatient monitoring and provide
a more acceptable way for women to monitor their blood
pressure [38]. There is evidence that home blood pressure
monitoring is safe provided the reference ranges for target
blood pressures are lower than in the clinic setting [37, 38].
In obese pregnant women, the use of an appropriate sized cuff
is important in ensuring accurate blood pressure readings [20].
Home blood pressure monitoring can not only enable clos-
er and more accurate monitoring, but can also help to enable
appropriate diagnosis and initiation of antihypertensive med-
ication. According to the NICE guidance, the first line medi-
cation in the treatment of hypertension in pregnancy is
labetalol, followed by nifedipine and methyldopa [39].
There is no particular mention regarding any difference in
the choice of antihypertensive therapy in the obese pregnant
woman. With the adjunct of a home blood pressure monitor
that has been validated for use in pregnancy and a specially
designed smartphone app, women’s blood pressure can be
monitored remotely and antihypertensive treatment can be
titrated appropriately without compromising safety [38].
This innovative pathway has also been shown to be cost sav-
ing in UK NHS healthcare setting [40].
Discussion
A range of different methods to tackle hypertension in obese
pregnant women have been put forward, some are more
effective than others. Insufficient resources have targeted the
provision of a holistic preconception counselling service. In
the few places where this service is provided, it is not being
accessed enough and women are not attending, as it is associ-
ated with the stigma of over-medicalisation and the fear of
pregnancy complications [9]. Pre-pregnancy counselling rep-
resents a unique window of opportunity to address weight
issues in order to enter a pregnancy in better health with the
prospect of better outcomes for bothmother and baby [13, 16].
It appears that limiting weight gain during the pregnancy itself
is too little of an intervention too late in the process [17, 18].
A number of pharmacological approaches are being intro-
duced. Aspirin at a dose of 150 mg once a day initiated before
16weeks gestation is by far the drugwith the most evidence of
being effective at reducing preterm pre-eclampsia [25].
Metformin has some promise but larger studies are needed
in the context of obesity in order to elucidate whether it truly
is beneficial in reducing hypertensive disease in pregnancy
[30]. The evidence from clinical trials for the use of statins is
awaited and also holds some promise based on pre-clinical
trials [33].
With the advent of smartphones and evolving technologies,
home blood pressure monitoring may become the mainstay of
the management of hypertensive diseases both during the
pregnancy and postnatally in the community [37, 38]. This
will hopefully achieve better blood pressure control and re-
duce the need for as many hospital visits without jeopardising
maternal and fetal outcomes [38].
It is clear that with a growing obese population, determin-
ing the most effective treatment options and lifestyle recom-
mendations will have increasing importance and is likely to
influence care pathways and service provision.
Conclusions
Obesity is a growing health concern that is affecting an in-
creasing number of pregnancies and presents a multi-faceted
challenge to providers of maternity care. It is associated with
multiple co-morbidities and has a direct linkwith hypertensive
disease of pregnancy. Individualised, holistic, preconception
care is lacking and needs to be more readily available.
Pregnancies identified as high risk for developing hyperten-
sive disease should be more closely monitored, possibly with
the help of home blood pressure monitoring, and low-dose
aspirin should be started before 16 weeks’ gestation. Further
research needs to be undertaken to determine the role that
metformin and statins have on reducing the risk of hyperten-
sive disease in pregnancy. Close ties between hospital and
community care, in the preconception, antenatal, and postnatal
periods, can support women to limit weight gain, make in-
formed choices and time first and subsequent pregnancies so
that they have optimised their health and reduced their BMI.
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